• Japanese
  • Korean
  • Chinese
Cover Image

Kombiglyze XR (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Kombiglyze XR (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Kombilgyze XR sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Kombiglyze XR including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Kombiglyze XR including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2010-2020 for Kombiglyze XR in each of the US and EU5 markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Diabetes
  • 2.2. Epidemiology
    • 2.2.1. Prevalence
    • 2.2.2. Mortality
  • 2.3. Etiology and Risk Factors
    • 2.3.1. Obesity
    • 2.3.2. Sedentary Lifestyle
    • 2.3.3. Family History and Genetics
    • 2.3.4. Ethnicity
    • 2.3.5. Old Age
  • 2.4. Economic Impact of Diabetes
  • 2.5. GlobalData Report Guidance

3. Type 2KKKKK Diabetes: Market Characterization

  • 3.1. Type 2KKKKK Diabetes Market
  • 3.2. Type 2KKKKK Diabetes Market Forecasts
  • 3.3. Type 2KKKKK Diabetes Market: Drivers and Restraints
    • 3.3.1. Drivers
    • 3.3.2. Restraints

4. Classification of Diabetes

  • 4.1. Types of Diabetes
    • 4.1.1. Type 1KKKKK Diabetes
    • 4.1.2. Type 2KKKKK Diabetes
    • 4.1.3. Gestational Diabetes
  • 4.2. Diabetes Complications
    • 4.2.1. Cardiovascular Disease
    • 4.2.2. Nephropathy
    • 4.2.3. Neuropathy
    • 4.2.4. Amputation
    • 4.2.5. Retinopathy

5. Evolution of Anti-Diabetic Treatments

6. Medications

  • 6.1. Insulin
  • 6.2. Oral Medications
    • 6.2.1. Sulfonylureas (SUR)
    • 6.2.2. Biguanides (BGDs)
    • 6.2.3. Alpha-Glucosidase Inhibitors (AGI)
    • 6.2.4. Meglitinides
    • 6.2.5. Thiazolidinediones (TZDs)
    • 6.2.6. Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
    • 6.2.7. Oral Combination Therapy
  • 6.3. Other Injectionable Medications
    • 6.3.1. Pramlintide
    • 6.3.2. Exenatide
  • 6.4. Market Share as per Classes in Type 2KKKKK Diabetes

7. Kombiglyze XR

  • 7.1. Introduction
  • 7.2. Mechanism of Action
  • 7.3. Clinical Studies
    • 7.3.1. Study of Kombiglyze XR in Patients with Inadequate Control on Diet and Exercise Alone
    • 7.3.2. Study of Kombiglyze XR in Patients with Inadequate Control on Prior Metformin Monotherapy
  • 7.4. Approval Of Kombiglyze XR
  • 7.5. Factors Affecting Sales of Kombiglyze XR
    • 7.5.1. Improved Glycemic Control
    • 7.5.2. Adverse Events
    • 7.5.3. Increased Risk of Lactic Acidosis
    • 7.5.4. Efficacy profile
    • 7.5.5. Competition
  • 7.6. Drug Evaluation
    • 7.6.1. Drug Risk Benefit Score
    • 7.6.2. Intensity of Competition
  • 7.7. Sales Forecasts
    • 7.7.1. Target Patient Pool for kombiglyze XR
    • 7.7.2. Dosing
    • 7.7.3. Annual Cost of Therapy
    • 7.7.4. Market Penetration
    • 7.7.5. Sales Forecasts of Kombiglyze XR

8. Diabetes Market: Appendix

  • 8.1. Market Definitions
  • 8.2. List of Abberiviations
  • 8.3. Research Methodology
    • 8.3.1. Coverage
    • 8.3.2. Secondary Research
    • 8.3.3. Forecasting
    • 8.3.4. Number of patients approved to take the drug
    • 8.3.5. Net Penetration of Drug
    • 8.3.6. Net Annual Dosing
    • 8.3.7. Annual Cost of Therapy
  • 8.4. Drug Sales Estimates Model
  • 8.5. Contact Us
  • 8.6. Disclaimer
  • 8.7. Sources

List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trails
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
  • Table 8: Diabetes Drugs Evolution
  • Table 9: Results of 24-Week Placebo Controlled Trial of Kombiglyze XR in Treatment Naive Patients
  • Table 10: Results of 24-Week Placebo Controlled Trial of Kombiglyze XR in Patients with Inadequate Control on Prior metformin Monotherapy
  • Table 11: Safety Comparison of Kombiglyze XR with Janumet
  • Table 12: Efficacy Values of Kombiglyze XR
  • Table 13: Efficacy Comparison of Kombiglyze XR with its Competitors
  • Table 14: Drug Risk Benefit Score, Kombiglyze XR
  • Table 15: Efficacy Comparison of Kombiglyze XR with its Competitors
  • Table 16: Kombiglyze XR, Type 2 Diabetes, Global, Sales Estimates ($m), 2010-2020
  • Table 17: Kombiglyze XR, Type 2 Diabetes, The US, Sales Estimates ($m), 2010-2020
  • Table 18: Kombiglyze XR, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2012-2020
  • Table 19: Kombiglyze XR, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020
  • Table 20: Kombiglyze XR, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2020
  • Table 21: Kombiglyze XR, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2020
  • Table 22: Kombiglyze XR, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2012-2020

List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
  • Figure 3: Diabetes, World, Mortality, 2010
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020
  • Figure 6: Mechanism of Action of Sulfonylureas
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
  • Figure 9: Mechanism of Action of Thiazolidinediones
  • Figure 10: Mechanism of Action of DPP IV Inhibitors
  • Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010
  • Figure 12: Kombiglyze XR, Type 2 Diabetes, Global, Sales Estimates ($m), 2010-2020
  • Figure 13: Kombiglyze XR, Type 2 Diabetes, The US, Sales Estimates ($m), 2010-2020
  • Figure 14: Kombiglyze XR, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2012-2020
  • Figure 15: Kombiglyze XR, Type 2 Diabetes, France, Sales Forecasts ($m), 2012-2020
  • Figure 16: Kombiglyze XR, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2012-2010
  • Figure 17: Kombiglyze XR, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2012-2010
  • Figure 18: Kombiglyze XR, Diabetes, Spain, Sales Forecasts ($m), 2012-2020
  • Figure 19: Kombiglyze XR, Type 2 Diabetes, Global, Sales Distribution (%), 2020
  • Figure 20: Patients Approved for the Drug
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top